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Cytotoxic chemotherapy is one of the principal causes of anaemia
in patients with cancer. It may become progressively worse with
repeated cycles of chemotherapy (Kuzur and Greco, 1980), and
frequently aggravates pre-existing anaemia that is a common
occurrence in these patients. Thus, patients may experience an
overall worsening of their condition as a result of the additional
debilitating symptoms of anaemia. Palliative transfusions are often
administered in an attempt to ameliorate some of these effects.
However, allogeneic transfusion per se is associated with a risk of
adverse effects, such as bacterial, viral contamination, iron over-
load, rash, itching and other reactions (Walker, 1987). There is
also some evidence that blood transfusion can suppress the
immune system, which in turn influences the immune surveillance
of cancer and cancer recurrence rates (Blumberg and Heal, 1994).
Chemotherapy regimens containing cisplatin or carboplatin are
particularly associated with a high requirement for transfusions.
Moderate-to-severe anaemia occurs in 10–40% of patients treated
with cisplatin (Hesketh et al, 1988; Gebbia et al, 1990), although
the incidence may be increased still further with high dosages. In a
recent study by Kaye et al (1992), for example, transfusions were
required by 53% of patients treated with a median total cisplatin
dose of 500 mg m–2 for ovarian cancer. Moreover, anaemia appears
to occur in a similar percentage of patients treated with carboplatin
(59%) (Canetta et al, 1985).
Endogenous erythropoietin (EPO) production in response to
anaemia is known to be inadequate in anaemic cancer patients
compared with patients with iron deficiency anaemia. This relative
lack of EPO is further exacerbated by cytotoxic chemotherapy
(Miller et al, 1990). Similarly, blunted EPO responses are seen
in patients with non-cancer-related anaemia of chronic disease
(ACD), such as rheumatoid arthritis (Baer et al, 1987) but not in
those with anaemia due to other causes such as iron deficiency or
acute blood loss. It has been speculated that the maturation and
proliferation of EPO-producing cells may be directly affected by
the effects of nephrotoxic chemotherapeutic agents such as
cisplatin, thereby reducing EPO production (Rothman et al, 1985;
Miller et al, 1990). However, anaemia (in some cases severe) has
been reported in cisplatin-treated patients with no evidence of
underlying renal failure (Rothman et al, 1985). Also, no difference
has been observed in the EPO response to anaemia in patients
treated with cisplatin- and non-cisplatin-containing regimens.
Mechanisms other than nephrotoxicity may therefore cause the
blunting of the EPO response (Rothmann et al, 1985).
Several studies in anaemic chemotherapy-treated patients have
shown increased haemoglobin (Hb) levels and decreased red blood
cell (RBC) transfusion requirements following treatment with
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Summary Anaemia commonly occurs in cancer patients receiving chemotherapy, often necessitating blood transfusion. This multicentre
study was designed to evaluate the efficacy and safety of epoetin a in preventing the decline in haemoglobin (Hb) level, and to determine
whether the transfusion requirement could be reduced, in patients receiving 4–6 cycles of primarily platinum-based combination cyclic
chemotherapy for small cell lung cancer (SCLC). A total of 130 non-anaemic SCLC patients were randomized to receive no additional
treatment (n = 44), epoetin a 150 IU kg–1 subcutaneously (s.c.) three times a week (n = 42) or 300 IU kg–1 s.c. three times a week (n = 44).
Reductions in epoetin a dosage were made during the study if Hb level increased to >15 g dl–1. The mean weekly dosage was 335 and
612 IU kg–1, respectively, in the two active treatment groups. Significantly fewer (P < 0.05) epoetin a-treated patients experienced anaemia
(Hb < 10 g dl–1) during the course of chemotherapy (300 IU kg–1, 39%; 150 IU kg–1, 48%; untreated, 66%). This was reflected in the
significantly lower number of treated patients transfused [300 IU kg–1, 20% (P < 0.001); 150 IU kg–1, 45% (P < 0.05); untreated, 59%]. Epoetin
a was well-tolerated, and there was no evidence of sustained, clinically significant, hypertension. In summary, epoetin a is effective and
well-tolerated in maintaining Hb level and reducing transfusion requirement in patients undergoing cyclic chemotherapy for SCLC.
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epoetin a in patients with a variety of malignant diseases; more-
over, epoetin a was well-tolerated (Henry et al, 1989; Ludwig
et al, 1990, 1993a, 1993b; Abels, 1993; Cascinu et al, 1993; Case
et al, 1993). More recently a non-randomized phase IV study with
data available on 2030 patients was reported. Epoetin a resulted in
a 50% decrease in the number of patients requiring transfusion
independent of malignancy type and a reduction in the number of
units of red cells transfused per patient per month (Glaspy et al,
1997). Prophylactic epoetin a studies have had relatively little
attention in advanced solid malignancies. A small randomized
study of 62 patients with early stage breast cancer receiving
chemotherapy demonstrated that Hb levels were maintained close
to baseline levels in epoetin-treated patients whereas in the control
group there was progressive anaemia (Del Mastro et al, 1997).
Recent studies have indicated that lung cancer is associated
with a particularly high requirement for transfusion following
chemotherapy (Skillings et al, 1993), possibly because of poor
tolerance of anaemia in this patient population. A subgroup of the
total study population presented in the Results section was
analysed to determine the effects of epoetin a on erythroid pro-
genitors in the bone marrow. Essentially, the findings were that the
erythroid progenitors were reduced in the marrow of small cell
lung cancer (SCLC) patients compared with non-malignant
controls. Epoetin increased the level of erythroid progenitors when
assayed 1 month after chemotherapy had been completed
compared with a non-epoetin a-treated patient group (de Campos
et al, 1995). The aim of the current study was to determine the
efficacy and safety of epoetin a in preventing the decline in Hb
level in patients undergoing cyclic chemotherapy for SCLC, and to
evaluate whether a reduction in RBC transfusion requirements
could also be achieved. The impact of epoetin a therapy on
patients’ quality of life (QOL) was also assessed.
PATIENTS AND METHODS
Male or female patients (aged 18–75 years), planned for treatment
with 4–6 cycles of combination chemotherapy, primarily platinum-
based, for SCLC were enrolled in this open-label, randomized,
parallel-group, multicentre study. Chosen chemotherapy regimens
and doses were at the discretion of the investigator. The first cycle of
chemotherapy was started on day 1 of study enrolment; subsequent
cycles were administered approximately every 4 weeks. The
maximum study duration was 26 weeks. All patients were required
to be ambulatory and at least capable of self care – World Health
Organization (WHO) performance score ≤ 2 (Miller et al, 1981).
Further inclusion criteria were: Hb level ³ 10.5 g dl–1, neutrophil
count > 3000 mm–3, platelet count > 100 000 mm–3, no clinically
relevant abnormalities of renal or hepatic function, serum calcium <
10.6 mg dl–1 and stool samples negative for occult blood. Patients
were excluded if they were pregnant or of childbearing potential and
not taking adequate contraceptive measures, or if they had any clin-
ically significant disease, a history of primary haematological
disease, anaemia attributable to factors other than cancer and/or
chemotherapy, cerebral metastases, uncontrolled hypertension, a
history of seizures or acute illness within 7 days of study entry. In
addition, patients who had received androgen therapy within 2
months of study entry and those who had received any experimental
treatment, immunosuppressive drugs, or other agents known to
affect haematocrit, within 1 month prior to study entry, were
excluded, as were patients receiving haematopoietic growth factors
(including epoetin a) and those participating in another clinical trial.
The study was performed in accordance with the Declaration of
Helsinki (1964) revised in Tokyo (1975), and the subsequent
Venice (1983) and Hong Kong (1989) amendments. Approval of
the protocol by local Ethical Review Committees was also
obtained.
After providing written informed consent, patients were random-
ized to one of three groups: subcutaneous (s.c.) epoetin a 150 or
300 IU kg–1 three times per week (at intervals of 2–3 days), or no
epoetin a (untreated control). It was considered inappropriate to
give placebo injections to the control group because of the increased
risk of thrombocytopenia-related bruising. Epoetin a (EprexTM,
Procrit®, Erypo®) was supplied by the RW Johnson Pharmaceutical
Research Institute. Treatment with epoetin a was started 1 day after
administration of each cycle of chemotherapy and continued until 3
days prior to the following cycle; treatment continued for 1 month
after the final cycle. If the Hb level exceeded 15 g dl–1, epoetin a
was discontinued until the value had fallen to < 13 g dl–1, at which
point treatment was reinstated at half the initial dose. Transfusions
were allowed as necessary, e.g. for symptomatic anaemia.
Concomitant use of androgens was not permitted, and no patient
received iron supplementation during the study.
Baseline assessments included medical history and physical
examination, a listing of all current therapies, determination of
vital signs, a 12-lead electrocardiogram (ECG) recording and
laboratory parameters, a QOL questionnaire in which patients’
responses to three questions (energy level, daily activity and
overall QOL) were scored on a 100 mm visual analogue scale, and
WHO performance score. Bone marrow aspirates and trephine
biopsies were performed only if they formed part of the normal
staging procedure prior to chemotherapy. Serum EPO levels were
determined at the start of the first chemotherapy cycle only.
Laboratory parameters and concomitant therapies were docu-
mented at the start of each cycle; haematological parameters were
also assessed mid-cycle and, if the following cycle was delayed, at
the planned start of the next cycle. Vital signs and adverse events
were also determined after each s.c. injection of epoetin a. Final
evaluations at study end included a physical examination, infor-
mation regarding study withdrawal, QOL indices and WHO
performance score, the physician’s global assessment, a 12-lead
ECG recording and assessment of laboratory parameters. The
presence of epoetin a antibodies was determined both at the start
of the study and at completion.
Assessment of efficacy
The primary efficacy assessment was the prevention of anaemia,
defined as the maintenance of a Hb level ³ 10 g dl–1. Secondary
parameters were the number of RBC units transfused per patient
and per cycle, and the pattern of Hb and haematocrit levels during
the course of chemotherapy. Patient well-being in the week prior
to each cycle of chemotherapy was assessed by the QOL question-
naire and WHO performance score. Safety assessments included
patient discontinuation information, vital signs (recorded in the
treated groups only) and the incidence and severity of adverse
events, laboratory parameters at the start of each cycle, and
epoetin  a antibody titre at study end compared to baseline.
Statistical analyses
Comparability of the three groups with regard to demographic and
clinical characteristics at baseline was tested by means of analysis398 N Thatcher et al
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of variance (ANOVA), Kruskal–Wallis or c2 tests, as appropriate.
Differences between treatment groups for mid-cycle Hb and
haematocrit through cycles 1–6 were tested using ANOVA.
Within-group differences from baseline for efficacy parameters
were tested using a paired Student’s t-test. The proportion of
patients transfused was compared between treatment groups using
a Cochran–Mantel–Haenszel analysis. For pairwise comparison of
treatment groups, the sequentially rejective Bonferroni–Holm
procedure was applied to adjust for the three multiple compar-
isons. The time to become anaemic or require transfusion was
analysed by survival analysis using Kaplan–Meier estimates and
the log-rank test. All tests were conducted at the two-sided, 0.05
significance level.
RESULTS
A total of 130 patients were enrolled (untreated, n = 44; epoetin
a 150 IU kg–1, n = 42; epoetin a 300 IU kg–1, n = 44). All patients
were eligible for inclusion in the efficacy analysis.
The demographic and clinical characteristics of the three groups
at baseline are summarized in Table 1. Overall, there were no
statistically significant between-group differences. Hb levels were
within the normal range and neutrophil and reticulocyte counts
were not depressed. The majority of patients received cytotoxic
drug regimens containing either carboplatin (82%) or cisplatin
(7%). The most frequently administered combination (n = 39) was
the VICE regimen (etoposide 120 mg m–2 intravenously (i.v.) on
days 1 and 2 (followed by 240 mg m–2 orally on day 3); carboplatin
300 mg m–2 i.v. and ifosfamide 5 g m–2 i.v. on day 1; and
vincristine 1 mg on day 14). The majority of patients (n = 69)
received combinations of two or three of these agents or cisplatin
plus etoposide. Other chemotherapeutic agents used during the
study included doxorubicin, cyclophosphamide, epirubicin,
methotrexate and lomustine.
More than 75% of patients completed at least 4 cycles of
chemotherapy, with a mean number of 4.7 cycles per patient, 80%
of cycles were administered on time. Cycle length was comparable
between treatment groups and the number of patients per cycle in
each group declined at approximately the same rate, suggesting
that a similar drop out in these patient groups would be unlikely to
influence the results. All patients were, therefore, evaluated for
efficacy according to cycle.
In total, 42 patients prematurely discontinued the study
(Table 2). The most common reasons for study withdrawal were
death (nine patients), adverse events (seven patients) and other
reasons (22 patients). The number of patients withdrawn was
comparable in the three groups.
Epoetin a dosage reductions, required at some time during the
study because of an increase in Hb level to >15 g dl–1, was required
in nine patients (21%) initially treated with epoetin a 150 IU kg–1
and in 17 (39%) of the epoetin a 300 IU kg–1 group. As a result of
the omission of treatment with epoetin a during chemotherapy in
some patients, the mean weekly dosages of epoetin a in the two
groups were 335 and 612 IU kg–1 respectively.
Transfusion requirements and haematological
response
A significantly higher percentage of patients in the untreated group
experienced anaemia (Hb < 10 g dl–1) during the study (66%)
compared with patients treated with either epoetin a 150 IU kg–1
(48%; P < 0.05) or 300 IU kg–1 (39%; P = 0.005). The difference
was particularly apparent during cycles 2–5, but then became less
evident (Figure 1).
The probability of patients requiring no transfusions during the
study is shown in Figure 2. The beneficial effect of epoetin a was
evident by the second cycle of treatment and persisted throughout the
study. Overall, 26/44 patients (59%) in the untreated group required
Table 1 Demographic and clinical characteristics at baseline
Parameter Untreated Epoetin a Epoetin a
(n = 44) 150 IU kg–1 (n = 42) 300 IU kg–1 (n = 44)
Male/female (n) 27/17 26/16 29/15
Median age, years (range) 60.0 (39–74) 59.0 (43–72) 58.5 (30–72)
Median weight, kg (range) 63.8 (44–108) 65.2 (43–107) 70.8 (42–95)
Median height, cm (range) 166.5 (150–185) 168.0 (145–189) 172.0 (150–187)
Median Hb level, g dl–1 (range) 13.4 (10.9–16.4) 13.7 (10.7–16.1) 13.6 (10.9–17.0)
Median Hct, % (range) 39.4 (32.3–46.8) 41.0 (32.6–50.3) 40.0 (31.8–49.4)
Median reticulocyte count, 39.3 (0.1–109.1) 40.1(1.0–76.2) 42.0 (5.1–112.8)
´ 109 l–1 (range)
Median neutrophil count, 5.9 (2.9–16.4) 6.0 (1.7–11.3) 6.3 (2.6–14.9)
´ 109 l–1 (range)
Median WHO performance 1.0 (0–2) 1.0 (0–3) 1.0 (0–2)
score, 0–4 (range)
Median QOL scores,
0–100 mm (range)
Energy level 51.0 (0–94) 47.0 (11–100) 52.5 (0–100)
Daily activity 32.0 (0–97) 46.0 (5–100) 49.0 (0–100)
Overall QOL 49.0 (0–98) 44.0 (1–100) 50.5 (0–100)
Chemotherapy regimen (n)
Carboplatin-based 38 34 35
Cisplatin-based 2 2 5
Other 4 6 4
Hb = haemoglobin; Hct = haematocrit; QOL = quality of life; WHO = World Health Organization.Epoetin-a treatment in SCLC 399
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transfusions compared with 19/42 patients (45%) in the epoetin a
150 IU kg–1 group (P < 0.05) and only 9/44 (20%) in the epoetin a
300 IU kg–1 group (P < 0.001). The difference between the two
epoetin a groups was significant (P < 0.005). The total number of
transfusions administered in the three groups was 73, 41 and 25
respectively. The mean cumulative transfusion rate for the six cycles
was also significantly higher in the untreated group than in either the
epoetin a 150 IU kg–1 or 300 IU kg–1 groups (P < 0.01 and P < 0.001
respectively) (Table 3). The difference between the two epoetin a
groups was also significant (P < 0.05). The mean Hb level at first
transfusion varied between centres, ranging from 8.4 to 12.9 g dl–1
for the 150 IU kg–1 group, 8.7 to 10.8 g dl–1 for the 300 IU kg–1 group,
but 8.2 to 10.0 g dl–1 for the untreated group.
Mean Hb levels by cycle are shown in Figure 3. During the first
cycle, mean Hb did not differ significantly from baseline in any
group. However, during the second, third and fourth cycles there
were significant between-group differences for the reduction in Hb
level from baseline. Epoetin a not only reduced the mid-cycle
Hb nadir, but also significantly delayed the onset of anaemia
(Hb < 10 g dl–1) and/or the first RBC transfusion (P < 0.01). The
median time to become anaemic/require transfusion was 59/48,
116/98 and > 142/166 days in the untreated, epoetin a 150 IU kg–1
and 300 IU kg–1 groups respectively. Mean haematocrit values and
changes from baseline followed a similar pattern to that of Hb
levels (data not shown).
In order to assess the possibility that variations in the intensity
of chemotherapy accounted for the between-group differences in
Hb values, transfusion rates and the number of patients becoming
anaemic or becoming anaemic and/or requiring transfusion, the
proportion of patients with neutrophil counts < 1 ´ 109 l–1 was
determined as a surrogate marker of chemotherapy intensity. There
were no statistically significant differences between the treatment
groups with respect to the incidence of marked neutropenia (Table
4), suggesting that there were no differences in chemotherapy
intensity. In addition, the potential effects of differential trans-
fusion practices were determined from the mean Hb value within
7 days prior to transfusion. The results showed that patients in
the epoetin a 300 IU kg–1 groups were transfused at lower Hb
levels (8.0 g dl–1) than in either the epoetin a 150 IU kg–1 group
(8.6 g dl–1) or untreated patients (8.5 g dl–1), suggesting that
patients in the 300 IU kg–1 group may have been somewhat under-
transfused compared with patients in other groups.
QOL and WHO performance scores
Parameters assessed by the QOL questionnaire, namely energy
level, daily activity and overall QOL, did not show any marked
Table 2 Reasons for premature study discontinuation
Parameter Untreated Epoetin a Epoetin a
(n = 44) 150 IU kg–1 (n = 42) 300 IU kg–1 (n = 44)
Adverse events 2 4 1
Death 3 1 5
Intercurrent illness 1 1 2
Othera 81 0 4
Total 14 (32%) 16 (38%) 12 (27%)
aIncluding personal reasons, loss to follow-up, non-responder to
chemotherapy, disease progression or remission, discontinuation of
chemotherapy, toxicity of chemotherapy, elevated haemoglobin, deterioration
of general condition and physician decision.
Figure 1 Effect of epoetin a on the percentage of patients becoming
anaemic (haemoglobin level < 10 g dl–1) during cyclic combination (primarily
platinum-based) chemotherapy for small cell lung cancer; n = number of
patients
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Figure 2 Statistically significant effect (P = 0.0007; log-rank test) of epoetin
a on the probability of patients not requiring transfusions during cyclic
combination (primarily platinum-based) chemotherapy for small cell lung
cancer
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changes from baseline at the end of the study in any group, with
the exception of a significant improvement in overall QOL in the
epoetin a 150 IU kg–1 group (P < 0.05). There were no significant
between-group differences (Table 5), which may have been related
to the fact that all groups had similar Hb values at study end
(approximately 10–11 g dl–1). In this study of lung cancer patients
it was considered reasonable not to insist on a dogmatic haemo-
globin level for transfusion and deny the patient the benefits of
transfusion when needed, particularly in the control group. Not
surprisingly, given this policy, QOL at the end of the study was
similar in the three groups. Evaluation of WHO performance
scores revealed similar findings, with no significant between- or
within-group differences.
Tolerability
Both dosages of epoetin a were well-tolerated. As shown in
Table 6, the incidence and distribution of adverse events did not
differ markedly between the three groups. Moreover, the only
adverse event considered definitely related to epoetin a was a
localized swelling and burning sensation at the injection site in two
patients treated with the higher dosage. Premature discontinuation
as a result of adverse events was not influenced by epoetin a treat-
ment (Table 2). Myocardial infarction was documented in two
patients receiving epoetin a 300 IU kg–1, but the relationship to
therapy was unclear. None of the six deaths among epoetin
a-treated patients were causally related to treatment.
There was no evidence of a sustained increase in blood pressure
with either dosage of epoetin a. Among patients treated with
epoetin a 150 IU kg–1, one patient had several recordings of
diastolic blood pressure around 105 mmHg, while another patient
with a history of hypertension experienced an elevation of blood
pressure to 180/120 mmHg after the second dose. A third patient,
treated with epoetin a 300 IU kg–1, developed moderate hyperten-
sion (up to 180/115 mmHg) that regressed after the institution of
Table 3 Mean (± s.d.) cumulative transfusion rate for the six cycles and per
patient, by treatment group
Cumulative transfusion rate Untreated Epoetin a Epoetin a
(n = 44) 150 IU kg–1 (n = 42) 300 IU kg–1 (n = 44)
Units per six cycles 6.13 ± 7.13 3.84 ± 5.58 2.10 ± 4.60
Units per patient
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Table 4 Number of patients with neutrophil counts <1 ´ 109l–1 by cycle and
treatment group
Cycle Untreated Epoetin a Epoetin a
150 IU kg–1 300 IU kg–1
1 19/44 (43%) 21/42 (50%) 22/44 (50%)
2 22/42 (52%) 18/42 (43%) 25/41 (61%)
3 16/41 (39%) 14/39 (36%) 22/37 (59%)
4 14/34 (41%) 13/32 (41%) 17/35 (49%)
5 8/24 (33%) 12/25 (48%) 16/26 (62%)
6 8/21 (38%) 8/18 (44%) 16/23 (70%)
Total 30/44 (68%) 27/42 (64%) 37/44 (84%)
Figure 3 Effect of epoetin a on mean haemoglobin (Hb) levels at baseline, start of cycle and mid-cycle, in 130 patients receiving cyclic combination (primarily
platinum-based) chemotherapy for small cell lung cancerEpoetin-a treatment in SCLC 401
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anti-hypertensive therapy; this event may have been drug-related.
Overall, there was a significant reduction in mean systolic blood
pressure over time in both epoetin a treatment groups (P ≤ 0.01).
Low serum iron and transferrin saturation values were seen in
several patients, mainly in the low-dosage epoetin a group. In
some cases this may have been caused by ACD combined with
iron deficiency, as mean ferritin levels were normal or elevated.
There were no clinically significant, treatment-related changes
in physical examination, serum chemistry parameters or the ECG.
In addition, no antibodies against epoetin a developed during
treatment.
DISCUSSION
SCLC progresses rapidly in the absence of therapy. The optimal
response rates are achieved with combination chemotherapy
programmes. However, such treatment regimens are associated
with a significant level of myelosuppression that may necessitate
frequent blood transfusions, with their attendant problems.
The results of this open-label, controlled study demonstrate the
beneficial effects of treatment with epoetin a in patients undergoing
cyclic, primarily platinum-based, combination chemotherapy for
SCLC. Indeed, patients receiving epoetin a required significantly
fewer transfusions and had a significantly lower mean cumulative
transfusion rate than untreated patients. These findings were corrob-
orated by assessment of the haematological response. Although
patients had Hb levels that were either normal or bordering on
anaemia at the start of the study, the myelosuppressive effects of
chemotherapy were already evident after the first cycle of treatment.
By the second cycle, however, the protective effects of epoetin a
became apparent, with significantly higher Hb levels in both epoetin
a-treated groups than in untreated patients. This time-course of
events was as expected, in view of the fact that an increase in reticu-
locytes is usually seen 3–4 days after initiation of epoetin a-stimu-
lated erythropoiesis, with the Hb response following more slowly
thereafter. The maintenance of a higher Hb level in the epoetin a-
treated groups continued through the third and fourth cycles of treat-
ment, after which the differences between the groups became
somewhat less marked, possibly as a result of heavier use of transfu-
sions in the control group. Alternatively, since iron supplementation
was not administered during this study, iron deficiency in later
cycles may have led to a reduction in epoetin a efficacy (Eschbach
et al, 1978). Moreover, drop-outs as chemotherapy cycles
progressed, or problems resulting from repeated chemotherapy, such
as neutropenic sepsis, may have blunted the effects of epoetin a.
The possibility that variations in the intensity of chemotherapy may
have explained the differences in Hb values and transfusion rates
between groups was evaluated and considered not significant. The
threshold for transfusion clearly depends on symptoms in a vulner-
able patient group such as lung cancer. The tolerability of dyspnoea
and lethargy together with local transfusion policies which differ
from centre to centre and from country to country mitigated against
a rigid transfusion policy, e.g. haemoglobin of 8 g dl–1 or less.
However, we did obtain data for differences between centres who
regard transfusion trigger policies. A somewhat lower mean Hb
level prior to transfusion in the epoetin a 300 IU kg–1 group, may
have meant that patients in this treatment group were actually under-
transfused for the degree of anaemia. Thus, the efficacy of the
epoetin a 300 IU kg–1 regimen may have been exaggerated
compared with the 150 IU kg–1 regimen.
The absence of marked improvements in measures of QOL and
WHO performance score at study end compared with baseline was
not unexpected in view of the similar mean Hb levels in the three
groups during the last cycle. Also, these measurements were most
likely influenced by the design of the study as epoetin a therapy was
initiated before, rather than after, the onset of anaemia. Again, any
differences between groups may have been masked by the adminis-
tration of blood transfusions or the effects of repeated chemotherapy.
Table 5 Mean (± s.d.) baseline and change to end-point measurements of QOL parametersa
QOL Untreated Epoetin a Epoetin a
parameter 150 IU kg–1 300 IU kg–1
(0–100 mm)
Baseline Change Baseline Change Baseline Change
(n = 37) (n = 27) n = 37) (n = 33) (n = 38) (n = 32)
Energy level 48.4 ± 23.6 1.6 ± 23.9 53.6 ± 27.7 –2.3 ± 31.9 50.7 ± 28.4 3.2 ± 40.1
Daily activity 41.7 ± 28.1 10.8 ± 35.6 50.8 ± 29.3 3.0 ± 31.7 50.8 ± 29.5 4.9 ± 38.5
Overall QOL 47.9 ± 26.7 7.5 ± 29.1 49.0 ± 28.1 11.7 ± 30.6b 53.9 ± 28.3 6.0 ± 41.0
aPositive values indicate an improvement. QOL = quality of life; b P < 0.05 vs baseline.
Table 6 Adverse events reported by ³ 5% of patients in any treatment
group
Adverse event Untreated Epoetin a Epoetin a
(n = 44) 150 IU kg–1 (n = 42) 300 IU kg–1 (n = 44)
Anaemia 19 (43%) 14 (33%) 10 (23%)
Thrombocytopenia 9 (20%) 11 (26%) 9 (20%)
Bacterial 10 (23%) 8 (19%) 7 (16%)
infection
Nausea 6 (14%) 3 (7%) 7 (16%)
Neutropenia 8 (18%) 5 (12%) 6 (14%)
Pyrexia 7 (16%) 7 (17%) 5 (11%)
Dyspnoea 1 (2%) 1 (2%) 5 (11%)
Vomiting 5 (11%) 5 (12%) 4 (9%)
Dizziness 1 (2%) 3 (7%) 4 (9%)
Cough 0 0 4 (9%)
Headache 1 (2%) 2 (5%) 3 (7%)
Constipation 1 (2%) 2 (5%) 3 (7%)
Malaise 0 2 (5%) 3 (7%)
Urinary tract 0 0 3 (7%)
infection
Alopecia 3 (7%) 1 (2%) 2 (5%)
Oedema 0 4 (10%) 1 (2%)
Diarrhoea 2 (5%) 5 (12%) 1 (2%)
Rash 4 (9%) 5 (12%) 1 (2%)
Decreased WBC 3 (7%) 1 (2%) 1 (2%)
count
Lethargy 3 (7%) 1 (2%) 0402 N Thatcher et al
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In common with previously published findings (Ludwig et al,
1990; Abels, 1993), treatment with both dosages of epoetin a
showed excellent tolerability throughout the study. The incidence
and type of adverse events did not differ markedly between the three
groups, and epoetin a had no effect on the rate of premature study
discontinuation. A local swelling and burning sensation at the
site of injection was the only adverse event considered
definitely related to epoetin a treatment. This effect was seen in
just two patients, both of whom were in the 300 IU kg–1 group,
and may have been associated with large injection volumes or insuf-
ficient warming of the solution to room temperature before use.
In contrast to anaemia of end-stage renal disease, in which
20–30% of patients treated with epoetin a experience hypertensive
episodes (Radermacher and Koch, 1993), there was no evidence of
a significant increase in blood pressure in this study. In fact, there
was an overall significant reduction in mean systolic blood pres-
sure over time in both epoetin a treatment groups. There was no
indication of any other cardiovascular complications with epoetin
a therapy. However, significant hyptertension arising de novo, and
responsive to appropriate treatment, may have been related to
epoetin  a therapy in one patient. While such findings suggest that
hypertension can occur in cancer patients treated with epoetin a,
this is much less common than in patients treated with epoetin a
for renal anaemia.
The low serum iron and transferrin saturation seen in some
patients was thought to be related to ACD, combined with iron
deficiency. As epoetin a-accelerated erythropoiesis utilizes a
considerable amount of iron (Eschbach et al, 1978), patients may
require iron supplementation; the management of such supplemen-
tation may well have been inadequate in this study and should be
considered in subsequent investigations.
As response and survival among cancer patients may depend on
the administration of dose-intensive combination chemotherapy,
it is important that effective treatments are available to alleviate
(or even prevent) the toxic effects of such intensive treatment. This
study has demonstrated that epoetin a is effective and well-toler-
ated in maintaining Hb level ³ 10 g dl–1 and reducing transfusion
requirements in patients with SCLC undergoing primarily plat-
inum-based, cyclic combination chemotherapy. Consequently,
exposure to the risks associated with transfusion, such as infection
transmission, allergic reactions, iron overload and immunosupres-
sion, is reduced and the patient may be able to tolerate higher
levels of chemotherapy. These significant clinical benefits
were achieved with mean weekly doses of epoetin a 335 and 612
IU kg–1 in the two treatment groups. Consequently, a dosage
regimen of 150 IU kg–1 s.c. three times a week is appropriate, with
escalation to 300 IU kg–1, if necessary.
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